阿尔茨海默氏病中可归因于阿波利波蛋白E的比例
Dylan M Williams1,2, Sami Heikkinen3, Mikko Hiltunen3
1Division of Psychiatry, University College London, Maple House, 149 Tottenham Court Rd, London, W1T 7NF UK.
概括
阿波利波蛋白E (APOE) 基因显著影响阿尔茨海默病 (AD) 的风险. APOE ε3和 ε4等位基因占大多数AD病例和近一半的痴呆病例,突出显示APOE是预防的关键目标.
科学领域:
- 遗传学和基因组学 在
- 神经科学是一个神经科学.
- 流行病学 流行病学
背景情况:
- 阿波利波蛋白E (APOE) 基因是阿尔茨海默病 (AD) 的主要遗传风险因素.
- 了解APOE等位基因的归因负担对于制定有针对性的AD预防和治疗策略至关重要.
研究的目的:
- 量化阿尔茨海默氏病 (AD) 的比例,AD神经病理和所有原因的痴呆症归因于常见的APOE等位基因 (ε3和 ε4).
- 通过各种大型研究评估APOE变异对痴呆风险的影响.
主要方法:
- 来自英国生物银行 (UKB) 和FinnGen队列 (N > 450,000) 的遗传数据和电子健康记录的分析.
- 在A4研究中使用PET扫描检查粉样蛋白-β阳性 (N = 4415).
- 来自阿尔茨海默氏病遗传学联盟 (ADGC) 的神经病理学确认的AD病例分析 (N = 5007).
主要成果:
- 在不同队列中,APOE ε3和 ε4等位基因占阿尔茨海默病病例的71.5%至92.7%.
- 在A4研究中,这些等位基因对85.4%的脑粉样性粉症负责.
- 在UKB和FinnGen中,APOE ε3和 ε4分别导致了44.4%和45.6%的全因痴呆症.
结论:
- 大多数阿尔茨海默氏症和相当一部分全因痴呆症都归因于APOE ε3和 ε4等位基因.
- 针对APOE的干预措施代表了预防和治疗痴呆症的高优先级战略.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
4.6K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
